

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9960)

**SHARE PURCHASE PURSUANT TO THE
POST-IPO RSU SCHEME**

Reference is made to the Post-IPO RSU Scheme of the Company approved and adopted by the Board on June 22, 2021, a summary of the principal terms of which was set out in the Prospectus, which is available on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (<https://www.kindstar.com.cn>).

As disclosed in the Prospectus, according to the rules of the Post-IPO RSU Scheme, the Company may, among others, transfer to the RSU Trustee the necessary funds and instruct the RSU Trustee to acquire Shares through on-market transactions at the prevailing market price, so as to satisfy the Awards.

The aggregate number of Shares to be purchased by the RSU Trustee shall not exceed 8% of the issued share capital of the Company as of the date of approval of the Post-IPO RSU Scheme, being 54,337,129 Shares. The Shares so purchased will be used as Awards for selected participants under the Post-IPO RSU Scheme.

The above plan is based on the Company's current operational growth outlook while acknowledging recent market conditions and macroeconomic performance indicators, as well as the Company's continuous intention to encourage and retain key employees to make contributions to the long-term growth and profits of the Company.

As at the date of this announcement, no RSU has been granted or agreed to be granted under the Post-IPO RSU Scheme. The Board will determine at its absolute discretion such number of RSUs to be granted to selected participants under the Post-IPO RSU Scheme with such vesting criteria and conditions as it may deem appropriate.

The Company shall not instruct the RSU Trustee to acquire Shares through on-market transactions at the prevailing market price, where such action (as applicable) is prohibited under the Listing Rules, the SFO or other applicable laws from time to time.

DEFINITIONS

“Award(s)”	award(s) granted to selected participant(s) by the Board by way of RSU(s) in accordance with the Post-IPO RSU Scheme
“Board”	the board of directors of the Company
“Company”	Kindstar Globalgene Technology, Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands, and the issued Shares of which are listed on the Main Board of the Stock Exchange
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
“Prospectus”	the prospectus of the Company dated June 29, 2021
“Post-IPO RSU Scheme”	the post-IPO restricted share unit scheme adopted by the Company on June 22, 2021, the principal terms of which are set out in the section headed “Appendix IV – Statutory and General Information – E. Post-IPO RSU Scheme” in the Prospectus
“RSU(s)”	restricted share unit(s)
“RSU Trustee”	Kernelstar Limited, an independent and professional trustee appointed by the Company to act as the trustee of the RSU Scheme
“SFO”	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
“Shares”	ordinary shares of US\$0.00025 each in the share capital of the Company

By order of the Board
Kindstar Globalgene Technology, Inc.
康聖環球基因技術有限公司
HUANG Shiang
Chairman

Hong Kong, March 25, 2022

As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zhanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.